Federated Hermes, Inc. Madrigal Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $5.95 Million - $10.3 Million	-102,597 Reduced 29.95%	240,000 $17.2 Million
Q1 2022 May 13, 2022	BUY	$55.89 - $101.89 $19.1 Million - $34.9 Million	342,597 New	342,597 $33.6 Million
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $238,939 - $314,082	-3,303 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $203,631 - $272,946	-2,599 Reduced 44.04%	3,303 $264,000
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $571,924 - $809,579	5,884 Added 32688.89%	5,902 $575,000
Q3 2018 Nov 13, 2018	SELL	$207.3 - $300.31 $938,032 - $1.36 Million	-4,525 Reduced 99.6%	18 $4,000
Q2 2018 Aug 10, 2018	BUY	$101.55 - $313.9 $459,310 - $1.42 Million	4,523 Added 22615.0%	4,543 $1.27 Million
Q1 2018 May 09, 2018	SELL	$93.35 - $149.04 $24,831 - $39,644	-266 Reduced 93.01%	20 $2,000
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $4,840 - $11,976	123 Added 75.46%	286 $0
Q3 2017 Nov 13, 2017	BUY	$15.48 - $46.19 $2,523 - $7,528	163	163 $7,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.